Clinical trial registry record

Pembrolizumab in Elderly Patients With Advanced Lung Cancer

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 23, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03293680
Last registry update
October 23, 2024
Status
Completed
Phase
Phase 2
Sponsor
Spanish Lung Cancer Group
Enrollment
83
Countries
Spain
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
83
Population
ALL · 70 Years
Duration
2017-01-15 to 2023-07-15
Intervention
Pembrolizumab
Comparator
Not reported
Outcomes measured
Overall Survival — From the date of inclusion of the first patient to until end of follow up, up to 36 months.; Changes in Health-related Quality of Life With Lung Cancer Symptom Scale — Beginning of cycle 1 (week 1) and beginning…; Impact on Functional Assessments Measured With Barthel Scale — Beginning of cycle 1 (week 1), beginning of cycle 4 (wee…; Progression-free Survival (PFS) — From the inclusion date in the study until first progression or end of follow up, up…; Overall Survival Rate at 2 Years. — From the date of inclusion of the first patient until two years follow up visit, up…; OS for Patients With a PD-L1 Under 50% — From the initiation of treatment until end of follow up, up to 36 months; OS for Patients With a PD-L1 Greater Than or Equal to 50% — From the initiation of treatment until end of follow up, up…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON